恒瑞医药HRS-5965胶囊拟纳入优先审评程序

Core Viewpoint - Heng Rui Medicine's subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. has announced that its HRS-5965 capsule is proposed to be included in the priority review list by the National Medical Products Administration, targeting treatment for adult patients with paroxysmal nocturnal hemoglobinuria who have not previously received complement inhibitors [1] Company Summary - HRS-5965 capsule is a complement factor B inhibitor designed to suppress complement-mediated intravascular and extravascular hemolysis, thereby increasing hemoglobin levels [1] - Currently, the only drug targeting the same mechanism that has been approved for sale abroad is Novartis's Iptacopan capsule (Fabhalta) [1]